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Prandial–basal insulin regimens plus oral
antihyperglycaemic agents to improve mealtime glycaemia:
initiate and progressively advance insulin therapy in type 2
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Aims: To compare two progressive approaches [once-daily insulin glargine plus ≤3 mealtime lispro (G+L) vs. insulin lispro mix 50/50
(LM50/50) progression once up to thrice daily (premix progression, PP)] of beginning and advancing insulin in patients with type 2 diabetes
(T2D) and inadequate glycaemic control on oral therapy, with the aim of showing non-inferiority of PP to G+L.
Methods: Patients were randomized to PP (n = 242) or G+L( n= 242) in a 36-week, multinational, open-label trial. Dinnertime insulin LM
50/50 could be replaced with insulin lispro mix 75/25 if needed for fasting glycaemic control.
Results: Baseline haemoglobin A1c (HbA1c) were 9.5% (PP) and 9.3% (G+L); p = 0.095. Change in A1C (baseline to endpoint) was −1.76%
(PP) and −1.93% (G+L) (p = 0.097) [between-group difference of 0.17 (95% conﬁdence interval: −0.03, 0.37)]. Non-inferiority of PP to G+L
was not shown based on the prespeciﬁed non-inferiority margin of 0.3%. A1C was lower with G+L at weeks 12 (7.8 vs. 7.9%; p = 0.042),
24 (7.4 vs. 7.6%; p = 0.046), but not at week 36 (7.5 vs. 7.6%; p = 0.405). There were no signiﬁcant differences in percentages of patients
achieving A1C ≤7%, overall hypoglycaemia incidence and rate or weight change. Total daily insulin dosages at endpoint were higher with PP
vs. G+L (0.57 vs. 0.51 U/kg; p = 0.017), likely due to more injections (1.98 vs. 1.79; p = 0.011).
Conclusions: Both treatments progressively improved glycaemic control in patients with T2D on oral therapy, although non-inferiority of PP to
G+Lwasnotshown.HigherinsulindoseswereobservedwithPPwithnobetween-treatmentdifferencesinoverallhypoglycaemiaorweightgain.
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Introduction
Intensive glycaemic control can delay the onset and slow the
progression of diabetes-related complications in patients with
type 2 diabetes (T2D) [1,2]. The recently published 10-year
follow-up of the United Kingdom Prospective Diabetes Study
showed that early intervention with intensive glucose control
had a ‘legacy effect’: early intensive glucose control continued
to reduce microvascular complications, and also reduced the
risk for myocardial infarction and all-cause mortality during
10 years of post-trial follow-up [3].
Recentstudiessupporttheclinicalutilityofinitiatinginsulin
therapyearlyinpatientswithT2Dbyaddingasingleinjectionof
basalinsulintoanexistingoralregimeninordertoachieveand
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maintain target hemoglobin A1C (HbA1c) levels ≤7% [4–8].
As only 28–58% of patients starting on basal insulin analogues
in these studies achieved A1C levels <7% [8], ≤7% [5–7] or
≤7.5% [4], there is a potential opportunity to improve blood
glucose(BG)levelsbyaddingarapid-actinginsulinatmealtime
as recommended if basal insulin analogue is insufﬁcient [9].
The 3-year results of the Treating to Target in Type 2 Diabetes
(4-T) study suggest that most patients are likely to need a
second type of insulin [10].
Premixed formulationsthatcontainboth basaland prandial
insulin could also be used in starting or progressing insulin
therapy [5,11] but need more study [9,12]. Of patients receiv-
ing twice-daily injections of premix (i.e. biphasic) insulin,
∼42–48% achieved A1C <7% [8] or ≤7% [5,13], suggesting
potential room for improvement if the regimen is intensiﬁed.
In subjects without diabetes, ∼50% of daily insulin secretion is
basal and the remainder is postprandial [14]. Thus, an insulin
lispro mix of 50% insulin lispro protamine suspension and
50% insulin lispro (LM50/50)more closelyreﬂects physiologicoriginal article DIABETES, OBESITY AND METABOLISM
insulin secretion than other premixed formulations and is
hypothesized to provide reasonably similar clinical outcomes
as a separately dosed basal with bolus insulin regimen.
In this study, two progressive approaches to starting and
intensifyinginsulintherapyarecomparedinpatientswithT2D
and inadequate glycaemic control on oral therapy: premix
insulin progression (PP) with once- then twice- or thrice-
daily LM50/50 insulin administration vs. basal insulin glargine
initiated once daily then supplemented with one to three
prandialinsulin(lispro)injections[insulinglargineplusinsulin
lispro (G+L)] as needed to meet glycaemic targets.
Research Design and Methods
This 36-week, randomized, open-label, active-controlled trial
was conducted in nine countries (Australia, Canada, France,
Greece, India, Republic of Korea, Mexico, Russian Federation
andSpain)inaccordancewiththeprovisionsoftheDeclaration
of Helsinki and Good Clinical Practice guidelines. All patients
provided written informed consent. Eligible patients were men
and women, 30–80 years,with T2D, A1C 7.5–12.0%using ≥2
oral antihyperglycaemic medications (OAMs) for ≥90 days,
insulin na¨ ıve, capable and willing to use insulin injection
devices and self-monitoring of blood glucose (SMBG) levels.
Patients were excluded if they had ≥1 episode of severe
hypoglycaemia within the prior 6 months, body mass index
(BMI)>40 kg/m2,weretakingathiazolidinedionedosegreater
than what was indicated in combination with insulin, or
were taking glucose-lowering agents other than metformin,
sulphonylurea or thiazolidinedione, had functional capacity
classIII/IVcardiacdisease,impairedrenalfunction,activeliver
disease, or serum alanine transaminase levels >2t i m e st h e
upper limit of normal.
Study Medications and Treatments
Patients were randomized to treatment by country and strati-
ﬁed within country by sulphonylurea use and A1C (≤8.5a n d
>8.5%)throughaninteractivetelephonesystem.Mostpatients
started on either one 10 U injection of LM50/50 adminis-
tered with the locallyavailable insulin pen, mostlyHumaPen®
Luxura™ pen (Eli Lilly and Company, Indianapolis, IN, USA)
within15 minpriortotheeveningmealorone10Uinjectionof
insulin glargine (Lantus®) administered with the locally avail-
ableinsulinpen,mostlyOptiPen®Pro1orLantus®OptiSet®
(Sanoﬁ-Aventis, Paris, France) at approximately the same time
eachmorning.Ineithergroup,12Uwasthestartingdoseiffast-
ing blood glucose (FBG) was ≥10 mmol (180 mg/dl). Insulin
dose adjustments were made utilizing regimen-speciﬁc insulin
dose titration algorithms (Tables 1 and 2) to achieve target
FBG and preprandial BG levels <5.5 mmol/l (<100 mg/dl).
Reasonable periods of time were permitted for regimen titra-
tion and stabilization (Tables 1 and 2; ﬁgure 1). No additional
injectionswereallowedafterweek24toallowA1Cstabilization
with a particular regimen at study end (36 weeks); insulin dose
adjustmentsbasedonexistinginjectionswereallowed.Patients
continued their prestudy OAM regimens during the study.
Hypoglycaemia events were assessed as to incidence
(proportion of patients who experience hypoglycaemia), rate
Table 1. Insulin dose titration algorithm for LM50/50 or insulin lispro.
Fasting and preprandial Starting next day-
Bedtime BG (mg/dl)∗ BG (mg/dl)∗ prandial dose change†
(mg/dl) (mmol/l) (mg/dl) (mmol/l) (U)
<80 <4.4 <80 <4.4 −2
81–110 4.5–6.1 81–100 4.5–5.5 No change
111–139 6.2–7.7 101–139 5.6–7.7 +2
140–179 7.8–9.9 140–179 7.8–9.9 +4
≥180 >9.9 ≥180 >9.9 +6
BG,bloodglucoseinplasma-equivalentvalue;LM50/50,insulin lispro mix
50/50.
∗Investigators may request additional BG monitoring from patients and
assess other glucose values at other times when making dose-adjustment
decisions.
†Each patient’s dose should be assessed by the investigator at least on a
weekly basis and adjusted as needed for the ﬁrst 10 weeks of the study.
Thereafter, dose adjustments may occur at least once every 2 weeks for
the next 8 weeks, then every 3 weeks for the remaining 18 weeks of the
study. Total insulin dose should not be increased by more than 10 U/day
or 10% of the total daily insulin dose, whichever is greater. The prandial
dose change is applied to the meal immediately preceding the BG being
targeted. For example, the LM50/50 or insulin lispro dose at breakfast is
adjusted based on the prelunch BG; the lunchtime insulin dose based on
the predinner BG and the dinnertime insulin dose based on the bedtime
and/or fasting BG reading.
Table 2. Insulin dose titration algorithm for insulin glargine.∗
FBG from preceding 2 days† Dose change‡
(mg/dl) (mmol/l) (U)
<80 <4.4 −2
81–100 4.5–5.5 0
101–120 5.6–6.6 +2
121–140 6.7–7.7 +4
141–160 7.8–8.8 +6
≥161 ≥8.9 +8
FBG, fasting blood glucose in plasma-equivalent value.
∗The insulin glargine dose should not be increased if hypoglycaemia
occurred during the previous week.
†Based upon the average of at least two readings.
‡Each patient’s dose should be assessed by the investigator at least on a
weekly basis and adjusted as needed for the ﬁrst 10 weeks of the study.
Thereafter, dose adjustments may occur at least once every 2 weeks for the
next 8 weeks, then every 3 weeks for the remaining 18 weeks of the study.
Total insulin dose should not be increased by more than 10 U/day or 10%
of the total daily insulin dose, whichever is greater.
(per person per 30 days) and severity. Hypoglycaemia was
deﬁned as any time a patient experienced an associated sign
or symptom, or had a BG level of <3.9 mmol/l (<70 mg/dl),
evenifitwasnotassociatedwithsigns,symptomsortreatment.
Nocturnal hypoglycaemia was deﬁned as any hypoglycaemic
event that occurred between bedtime and waking. Severe
hypoglycaemia was deﬁned as an episode with symptoms
consistent with hypoglycaemia in which the patient required
theassistanceofanotherperson,andwasassociatedwitheither
a BG level of<2.8 mmol/l (50 mg/dl) or prompt recoveryafter
oral carbohydrate, glucagon or intravenous glucose.
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Start 1x/day insulin regimen
(LM50/50 or glargine)
Initial BG targets 
achieved?/ dose 
stabilized?a
All BG targets 
reached/maintained?b
Add injection and adjust 
dose to reach BG targetsc
All BG targets 
reached? (added 
dose stabilized?)
Add injection and adjust 
dose to reach BG targetsc
All BG targets 
reached? (added 
dose stabilized?)
No Yes Continue adjusting
dose
Yes
No
Yes
Patient continues 1x/day 
insulin regimen
Patient continues 2x/day 
insulin regimen
Patient continues 3x/day 
insulin regimen
Yes
No
No
￿For patients on G+L, add lispro injection to remaining meal not covered
￿For patients on LM50/50 tid for 
￿For patients already “stable”on LM50/50 tid or G+L, adjust doses as needed
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Start 1x/day insulin regimen
(LM50/50 or glargine)
Initial BG targets 
achieved?/ dose 
stabilized?a
Initial BG targets 
achieved?/ dose 
stabilized?a
All BG targets 
reached/maintained?b
All BG targets 
reached/maintained?b
Add injection and adjust 
dose to reach BG targetsc
All BG targets 
reached? (added 
dose stabilized?)
All BG targets 
reached? (added 
dose stabilized?)
Add injection and adjust 
dose to reach BG targetsc
All BG targets 
reached? (added 
dose stabilized?)
All BG targets 
reached? (added 
dose stabilized?)
No Yes Continue adjusting
dose
Yes
No
Yes
Patient continues 1x/day 
insulin regimen
Patient continues 1x/day 
insulin regimen
Patient continues 2x/day 
insulin regimen
Patient continues 2x/day 
insulin regimen
Patient continues 3x/day 
insulin regimen
Patient continues 3x/day 
insulin regimen
Yes
No
No
￿For patients on G+L, add lispro injection to remaining meal not covered
≥ 6 weeks and FBG >100 mg/dL, switch dinnertime LM50/50 to LM75/25
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Figure 1. Insulin intensiﬁcation ﬂow chart. aAt start, adjust insulin glargine based on fasting blood glucose (FBG); adjust LM50/50 based on bedtime
blood glucose (BG). bPremeal BG [4.4–5.6 mmol/l (80–100 mg/dl)] and bedtime BG [4.5–6.1 mmol/l (81–110 mg/dl)]. cBased on premeal and bedtime
BG readings, the appropriate insulin injection was added at the meal preceding the episode of hyperglycaemia. For example, for a patient with elevated
BG before dinner, an insulin injection at lunchtime would be introduced (dose based on BG reading and corresponding dose recommended in Table 1).
G+L, insulin glargine plus lispro; LM50/50, insulin lispro mix 50/50; LM75/25, insulin lispro mix 75/25.
Outcome Measures
The primary efﬁcacy measure was change in A1C from
baseline to endpoint. Secondary efﬁcacy measures were A1C,
percentages of patients achieving A1C ≤6.5, <7a n d≤7.0%
and 7-point SMBG proﬁles over time; insulin dose (total,
basal and prandial); number of injections per day; and safety,
including hypoglycaemia (described earlier), weight change
and treatment-emergent adverse events (TEAEs). Blood, urine
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and serum samples were collected at screening (week 2). A1C
was analysed by a central laboratory (Covance, Princeton,
NJ, USA).
Statistical Methods
The sample size for the primary analysis was calculated on
the basis of a two-sided test for non-inferiority with a 5%
signiﬁcance level. Assuming a standard deviation of 1.1%
for A1C, 213 patients completing the study per treatment
group would provide 80% power to meet the prespeciﬁed
non-inferiority limit of 0.3%. Patients who completed a 36-
week A1C measurement constituted the per-protocol analysis
population (primary analysis).
The primary outcome was analysed by an analysis of
covariance (ANCOVA) model with treatment, country, baseline
A1C,baselineA1Cstratumandsulphonylureauseascovariates.
If the upper limit was below 0.3% (PP−G+L), then PP was
non-inferior to G+L. Secondary outcomes (A1C at other time
points, SMBG, glycaemic variability, total insulin dose and
number of injections) were analysed by ANCOVA model, on the
intent-to-treat(ITT)dataset,with treatment, country,baseline
A1Cstratum,sulphonylureauseandbaselineascovariates.The
percentages of patients achieving A1C goals (≤7.0, <7.0 and
≤6.5%)wereanalysedbylogisticregressionanalysiswithterms
for treatment, country, sulphonylurea use and baseline A1C.
Safety assessments were based on the entire randomly
assigned population. The proportion of patients reporting
at least one hypoglycaemic event or a severe hypoglycaemic
event was compared using Fisher’s exact test. Hypoglycaemic
rate and severe hypoglycaemicrate were analysed using ranked
analysis of variance (ANOVA) with treatment, country, baseline
A1C stratum and sulphonylurea use as covariates. Categorical
safety variables were compared between groups with Fisher’s
exact test.
Results
Patient Disposition and Baseline Characteristics
Patient disposition is shown in ﬁgure 2. A total of 211 (87.2%)
patients in the PP group and 215 (88.8%) patients in the G+L
group completed the study. Patient demographic and baseline
characteristics were similar between the PP and G+Lg r o u p s
for all measures except FBG, which was signiﬁcantly lower in
the G+Lv s .P Pg r o u p( T a b l e3 ) .
Glycaemic Control
Baseline A1C was similar in both groups (Table 3). Non-
inferiority of PP to G+L was not achieved for A1C change
from baseline to endpoint as the upper limit of the 95%
conﬁdence interval (CI) (−0.03, 0.37) was >0.3% (ﬁgure 3A).
The A1C change from baseline to endpoint [least-squares
mean (LSM) ± standard error (s.e.)] was −1.76 ± 0.37% for
thePPgroup(n = 188)and−1.93 ± 0.36%fortheG+Lgroup
(n = 195),abetween-groupdifferencethatwasnotstatistically
signiﬁcant (0.17%; p = 0.097). Over the course of the study,
A1C (LSM ± s.e.) declined in both groups (ﬁgure 3B). At
Table 3. Baseline demographics and characteristics of randomly assigned
patients.
Treatment group
G+L( n= 195) PP (n = 188)
Age (years) 59.9 ± 9.65 8 .9 ± 8.8
Sex (male : female) 101 (51.8) : 94 (48.2) 86 (45.7) : 102 (54.3)
Race/ethnicity
Caucasian 116 (59.5) 110 (58.5)
Hispanic 32 (16.4) 33 (17.6)
Black/African descent 0 (0.0) 1 (0.5)
East Asian 20 (10.3) 19 (10.1)
West Asian 27 (13.8) 25 (13.3)
(Indian subcontinent)
Weight (kg) 78.8 ± 15.27 8 .2 ± 15.3
BMI (kg/m2)2 8 .8 ± 4.52 9 .1 ± 4.4
Diabetes duration (years) 12.0 ± 7.31 1 .4 ± 5.6
A1C (%) 9.3 ± 1.29 .5 ± 1.2
FBG† (LSM ± s.e.)
mmol/l 9.6 ± 0.91 0 .2 ± 0.9∗
mg/day/l 172.8 ± 16.2 183.6 ± 16.2∗
Concomitant OAMs at study entry
Met/Sulph/TZD 21 (10.8) 20 (10.6)
Met/Sulph 163 (83.6) 163 (86.7)
Met/TZD 2 (1.0) 0 (0.0)
Sulph/TZD 9 (4.6) 5 (2.7)
Data are given as means ± s.d. or n (%) unless otherwise indicated.
A1C,hemoglobinA1C;BMI,bodymassindex;FBG,fastingbloodglucose;
G+L, insulin glargine plus insulin lispro; LSM, least-squares mean; Met,
metformin;n,thenumberofpatients;OAM,oralantihyperglycaemicagent;
PP,premixprogression(insulinlispromix50/50);s.d.,standarddeviation;
s.e., standard error; Sulph, sulphonylurea; TZD, thiazolidinedione.
∗p = 0.014; all other comparisons were not signiﬁcantly different.
†Calculated from the intent-to-treat population; all other values in the
table are based on the per-protocol population.
weeks 12 (PP, 7.93 ± 0.20%; G+L, 7.76 ± 0.20%; p = 0.042)
and 24 (PP, 7.59 ± 0.20%; G+L, 7.42 ± 0.20%; p = 0.046),
A1C was lower in the G+L vs. PP group; however, by week 36,
A1C values were not statistically different between groups (PP,
7.58 ± 0.20%; G+L, 7.50 ± 0.20%; p = 0.405). There were
no signiﬁcant differences between groups at endpoint in the
percentages of patients achieving A1C ≤7% (PP, 36.8%; G+L,
43.0%;p = 0.227), <7% (PP, 35.0%;G+L, 39.1%;p = 0.482)
and ≤6.5% (PP, 13.2%; G+L, 19.1%; p = 0.108), nor at any
12-week interval (data not shown).
At baseline, SMBG values (LSM ± s.e.) were sim-
ilar between groups at all time points except fasting,
which was signiﬁcantly lower in the G+L vs. PP group
[9.6 ± 0.9 mmol/l (172.8 ± 16.2m g / d l )v s .1 0 .2 ± 0.9 mmol/l
(183.6 ± 16.2m g / d l ) ; p= 0.014] (ﬁgure 3C). At endpoint,
both therapies signiﬁcantly reduced 7-point SMBG values
from baseline; fasting values were signiﬁcantly lower in the
G+L vs. PP group [6.5 ± 0.7 mmol/l (117.0 ± 12.6m g / d l )
vs. 7.0 ± 0.7 mmol/l (126.0 ± 12.6m g / d l ) ; p= 0.010], and
evening postprandial values were signiﬁcantly lower in the
PP vs. G+Lg r o u p[ 9 .8 ± 0.8 mmol/l (176.4 ± 14.4m g / d l )v s .
9.3 ± 0.9 mmol/l (167.4 ± 16.2m g / d l ) ;p= 0.010].
Among patients in the PP group, at endpoint (n = 234):
75 (32.1%) patients were on LM50/50 once daily (A1C:
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Discontinued
n=31 (12.8)
Reasons:
Adverse events=2 (6.4)
Patient Decision=12 (38.7)
Lost to follow-up=6 (19.3)
Other=11 (35.5)
G+L Completed 
n=215 (88.8)
PP Completed
n=211 (87.2)
Discontinued
n=27 (11.2)
Reasons:
Adverse events=1 (3.7)
Patient Decision=11 (40.7)
Lost to follow-up=1 (3.7)
Other=14 (51.9)
PP
n=242 (50.0)
Screen Failures
N=128
Discontinued (prior
to randomization)
N=24
Patients Entered Treatment
N=508
Patients Screened
N=636
G+L
n=242 (50.0)
Patients Randomized
N=484
Discontinued
n=31 (12.8)
Reasons:
Adverse events=2 (6.4)
Patient Decision=12 (38.7)
Lost to follow-up=6 (19.3)
Other=11 (35.5)
G+L Completed 
n=215 (88.8)
PP Completed
n=211 (87.2)
Discontinued
n=27 (11.2)
Reasons:
Adverse events=1 (3.7)
Patient Decision=11 (40.7)
Lost to follow-up=1 (3.7)
Other=14 (51.9)
PP
n=242 (50.0)
Screen Failures
N=128
Discontinued (prior
to randomization)
N=24
Patients Entered Treatment
N=508
Patients Screened
N=636
G+L
n=242 (50.0)
Patients Randomized
N=484
Figure 2. Patient disposition, the number (%) of patients. Other reasons for discontinuation were entry criteria not met, protocol violation, physician
decision, death and sponsor decision. G+L, insulin glargine plus insulin lispro; PP, premix progression (insulin lispro mix 50/50).
7.52), 65 (27.8%) patients were on LM50/50 twice daily
(morning + evening; A1C: 7.51), 17 (7.3%) patients were
on LM50/50 twice daily (mid-day + evening; A1C: 7.28),
66 (28.2%) patients were on LM50/50 thrice daily (A1C:
7.61) and 11 (4.7%) patients were on LM50/50 (morning) +
LM50/50(mid-day) + LM75/25(75%insulinlisproprotamine
suspension/25% insulin lispro) (evening) (A1C: 7.27). Among
patientsin the G+L group atendpoint (n = 235):108(46.0%)
patients were on insulin glargine once daily (A1C: 7.25), 62
(26.4%) patients were on G+L once daily (A1C: 7.24), 48
(20.4%) patients were on G+L twice daily (A1C: 7.69) and 17
(7.2%) patients were on G+L thrice daily (A1C: 6.85). Thus,
only patients treated with G+L thrice daily achieved a mean
A1C <7.0%;only a small number of patients were advanced to
this regimen.
Insulin Dose, Number of Injections and Weight Gain
Weight-adjusted total daily insulin dosages (LSM ± s.e.) at
endpoint were signiﬁcantly greater for the PP vs. G+Lg r o u p
(0.57 ± 0.11 vs. 0.51 ± 0.11 U/kg; p = 0.017). Most patients
e n d e du pt a k i n go n eo rt w oi n j e c t i o n s( P P ,6 7 % ;G +L, 72%;
p = 0.229). Mean number (LSM ± s.e.) of insulin injections
at endpoint was signiﬁcantly greater in the PP vs. G+Lg r o u p
(1.98 ± 0.3 vs. 1.79 ± 0.29; p = 0.011). Body weight (LSM ±
s.e.) change from baseline at endpoint was similar in both
groups (PP, 3.09 ± 1.44 kg; G+L, 3.19 ± 1.42 kg; p = 0.803).
Safety: Hypoglycaemia and Adverse Events
The incidence of overall (over the treatment period) all
hypoglycaemia [PP, 74.5% (n = 178); G+L, 74.6% (n = 179);
p = 1.00], nocturnal hypoglycaemia [PP, 46.9% (n = 112);
G+L, 46.7% (n = 112); p = 1.00] and severe hypoglycaemia
[PP, 3.4% (n = 8); G+L, 2.1% (n = 5); p = 0.416] was
similar in both groups. The incidence of all hypoglycaemia
at endpoint [last observation carried forward (LOCF)] broken
down bynumber ofinjectionsis provided in Table 4;statistical
comparisons were not made because of low numbers.
There was no statistically signiﬁcant difference between the
two groups for the overall all or overall nocturnal hypo-
glycaemic rate. Higher rates (mean ± s.d.) of hypoglycaemic
episodeswereobservedwithpatientsintheG+LgroupatLOCF
endpoint (2.19 ± 3.60 vs. 1.57 ± 2.98 episodes per patient per
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Figure 3. (A) Change in mean A1C ± s.e.m. from baseline to endpoint for G+L and PP groups and the difference (G+L − PP) in A1C change with the
95% conﬁdence interval (CI). (B) Mean A1C ± s.e.m. over the study for G+L and PP groups. (C) SMBG 7-point proﬁles at baseline and endpoint for
patients treated with G+L or PP; ∗p = 0.014 for comparison of baseline fasting values between treatment groups; †p = 0.010 for comparison of endpoint
fasting values between treatment groups; ‡p = 0.010 for comparison of endpoint evening 2-h PP values between treatment groups. A1C, hemoglobin
A1C; G+L, insulin glargine plus lispro; PP, premix progression (insulin lispro mix 50/50); s.e.m., standard error of mean; SMBG, self-monitored blood
glucose.
30 days; p = 0.022), corresponding to hypoglycaemia occur-
ring between the 24th and 36th week of treatment.
Overall,88(36.4%)patientsinthePPgroupand92(38.0%)
patients in the G+L group experienced at least one TEAE
during the study (p = 0.778). A small percentage of patients
in each group experienced a serious adverse event during the
study: 11 (4.5%) patients in the PP group and 10 (4.1%)
patients in the G+Lg r o u p( p= 1.00).There were three deaths
reported in the study (PP, n = 0; G+L, n = 3); none were
consideredtoberelatedtostudydrugordevice[coronaryartery
disease (n = 1), pulmonary edema (n = 1) and undetermined
(n = 1)].
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Table 4. Incidence of hypoglycaemia at endpoint (LOCF) by number of
injections.
Number of injections
12 3 4 5 ∗
G+L n 110 65 48 16 1
Hypoglycaemia, n (%) 44 (40) 31 (48) 22 (46) 9 (56) 0 (0)
P P n 6 59 48 0N A N A
Hypoglycaemia, n (%) 26 (40) 30 (32) 31 (39) NA NA
The incidence of hypoglycaemia was deﬁned as the number of patients
with at least one hypoglycaemic episode.
G+L, insulin glargine plus lispro; LOCF, last observation carried forward;
n, the number of patients; NA, not applicable; PP, premix progression
(insulin lispro mix 50/50).
∗One patient received two injections of insulin glargine (one dose in the
morning and one in the evening) plus three lispro injections.
Discussion
More evidence for the use of speciﬁc insulin regimens in
T2D is needed beyond the introduction of the starting insulin
regimen. This study evaluated two progressive regimens for
advancing insulin therapy in insulin-na¨ ıve patients with T2D
continuing prestudy OAMs. Both regimens started with once-
daily insulin injections and provided increasing mealtime
insulincoveragewithadditionalinjections,andbothresultedin
clinicallyrelevantdecreasesinA1Coverthecourseofthestudy.
While there was no statistically signiﬁcant difference between
groups in A1C reduction at endpoint and non-inferiority was
not shown, important observations in each approach may be
noteworthy to consider during clinical management.
During the ﬁrst 24 weeks, while patients in the G+Lg r o u p
were injecting once-daily insulin glargine and adding another
injection, patients’ mean A1C was signiﬁcantly lowered in
the G+L vs. PP group. From the 24th to 36th week, when
additionalmealtimeinsulininjectionswerenotintroducedbut
dosetitrationswereallowed,A1CincreasedslightlyintheG+L
group and, by endpoint, there were no signiﬁcant differences
betweenthegroups.Moststudiesevaluatingbasalinsulinadded
to OAMs in T2D note a decrease in A1C from baseline up to
∼12 weeks, after which they stabilize [4,5]; whereas, in the
present study, the improvement in A1C continued in the G+L
group until 24 weeks. Thus, additional efﬁcacy in lowering BG
wasobservedwhileadditionalmealtimeinsulinwasintroduced.
The G+L regimen more effectively lowered FBG compared
to the PP regimen, which is consistent with other studies
comparing premix to basal insulin analogues [5,8,11,12], and
prandial premixed therapy to basal/bolus therapy [15].
In the PP group, A1C decreased from baseline to 24 weeks
almost in parallel with the G+L group, although levels were
slightly higher. While PP patients had higher A1C at the 12th
and 24th week, patients in this group were able to maintain
their A1C levels between the 24th and 36th week; by the end
of week 36, there was no difference in A1C between groups.
The PP regimen more effectivelylowered evening postprandial
valuescomparedtoG+Ltherapy.Agreaternumberofpatients
inthePPvs.G+Lgroupwerereceivingmorethanoneinjection
by the end of week 24, which may explain why A1C levels were
maintained in this group.
The higher rate of hypoglycaemia in the G+L vs. PP group
occurred after week 24, a point after which no additional
mealtime lispro injections could be introduced. Because A1C
increased slightly in the G+L group between weeks 24 and 36,
the increased rate of hypoglycaemia is unlikely to be the result
of lower glucose levels but may have resulted from increasing
the insulin dose without adding injections. In contrast, the
greaternumber ofinjectionsinthePPgroupmayhaveallowed
administration of higher doses overall without increasing
hypoglycaemia. This ﬁnding is consistent with the rationale
behind multiple daily insulin (MDI) injections (i.e. four
injections per day with separate basal and bolus components),
where each injection provides a unique opportunity for more
ﬂexible dose adjustment [16] to improve glycaemic control
while avoiding hypoglycaemia.
Our ﬁndings are consistent with those of Rosenstock
et al. [15] in which LM50/50 with each meal and separately
dosed basal/bolus therapy both signiﬁcantly lowered A1C and
was also unable to show non-inferiority. Some important
differences and similarities between the two studies are
noteworthy. The Rosenstock et al. study included patients
already taking insulin and randomized to ﬁxed and intensive
regimens with three to four insulin injections, whereas the
insulin-na¨ ıvepatientsinourstudywerestartedononeinjection
then gradually escalated to up to three to four injections until
week 24. While most patients advanced therapy to more than
one injection, not many reached three to four injections; yet
within 24–36 weeks, mean A1Cs had dropped to ∼7.5%.
Considering that patients in the Rosenstock et al. study had
mean A1C of ∼9.0% at baseline while on once-daily basal
insulin (∼50 units/day), our results highlight the potential
improvement attainable by advancing to more than one
injection or providing mealtime insulin coverage to optimize
glycaemiccontrol.Whilegreaterweightgainhasbeenreported
with premixed vs. basal insulin regimens [12], there were
no weight differences between regimens in the Rosenstock
et al. [15] study or the present study. There were also no
differencesinhypoglycaemiabetweenregimensineitherstudy.
An important difference between the two studies is the
mean A1C levels at study endpoint. With the intensive insulin
therapies in the Rosenstock et al. study, mean A1C at endpoint
was<7.0%withbothtreatments;whereasinthepresentstudy,
mean A1C at endpoint was 7.6% while patients were on a
median of two insulin injections. The difference in achieved
mean A1Cs at endpoint again highlights the potential for
improvement in glycaemic control by advancing prandial
insulin to cover all meals.
Relatively few other studies have evaluated progressive
insulin advancement in the context of a clinical trial. The
Orals Plus Apidra and LANTUS (OPAL) study [17] evaluated
treatment intensiﬁcation in German patients with T2D not
optimally controlled on insulin glargine plus OAMs by adding
a single injection of rapid-acting insulin analogue glulisine
before breakfast or the main mealtime. This approach also led
to signiﬁcant reductions in A1C. One observational study [18]
employed a progressive titration of biphasic insulin aspart
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from one up to three injections (adding one injection every
16 weeks) in patients with T2D failing OAMs with or without
basal insulin, but this study did not have a comparator. By
evaluating the addition of ≥1 mealtime insulin injection,
employing randomization and active control and involving
many countries, the ﬁndings in this study may have broader
generalizability.
A limitation of the present study is the open-label design,
which was unavoidable given the cloudy vs. clear appearance
of the insulin preparations that prevented blinding. This may
have contributed to inequality in the numbers of injections
given that most practitioners use premix insulin twice daily
and insulin glargine once daily. While the protocol allowed
titration up to three to four injections, most patients only
went up to two injections in spite of endpoint A1Cs not being
<7%. It could be argued that tighter control should have been
implemented considering that lower A1Cs were achievable
with three to four insulin injections, as shown in Rosenstock
et al. [15]. The protocolincluded an optionto switch LM50/50
to LM75/25 if FBG targets were not achievable, and some
patients who switched achieved lower A1Cs. More stringent
guidelines in the study design for switching to LM75/25 may
have been warranted.
Theslightworseningofglycaemiccontrolin theG+Lgroup
after 24 weeks emphasizes the importance of being vigilant
about getting patients to achieve glycaemic control. The wide
variability in the change in A1C (95% CI: −0.03, 0.37) reﬂects
the broad differences in patients’ responses to these insulin
regimens. Other factors may need to be studied to better
understandthis.Theapparentresistancetoincreasingnumbers
ofinjectionsisareminderthattherearebarrierstointensifying
insulin therapy that also may need to be considered and
addressed to more effectively aim for better glycaemic control
earlier in the natural history of T2D. One of these barriers is
clinical inertia or failure of health-care providers to initiate or
advance therapy in a patient who is not at the recommended
therapeutic goal [19,20].
In summary, this study shows that both the PP and G+L
regimens are efﬁcient in lowering A1C even if non-inferiority
of PP to G+L could not be shown. These ﬁndings support
the belief that most patients with T2D will likely need more
than one type of insulin [5,10], and that targeting both fasting
and mealtime BG levels is important. These ﬁndings may aid
physicians as they choose and optimize insulin regimens for
individual patients with T2D.
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